The search revealed six larger studies analyzing the effects of different anti-VEGF medications in the treatment of IGS: four studies employed intravitreal bevacizumab (IVB), one dedicated to intravitreal ranibizumab (IVR) and one compared the efficacy of the available three agents: aflibercept, ranibizumab, and bevacizumab. Here, VEGFA is linked to megaloblastic anemia.